在治疗复发/难治性多发性骨髓瘤的1期临床试验中,TAK-573能够显著提高骨髓中被激活的CD8阳性T细胞数目。根据ClinicalTrial网站,目前TAK-573正在开展一项评估TAK-573在难治性多发性骨髓瘤患者中的安全性、耐受性、功效、药代动力学和免疫原性的1b/2期研究。 此外,另一项TAK-573单药或与默沙东(MSD)重磅PD-1抑制剂...
TAK580 (DAY 101) is a highly brain penetrant, pan-RAF kinase inhibitor, currently in clinical trials in pediatric low grade gliomas (NCT03429803, NCT04775485). Paxalisib combines synergistically with TAK580 to reduce AT/RT growth and viability (Bliss synergy score 24.22). A pilot study ...
Professor Tak Yeung LEUNG is the Chairman of the Department of Obstetrics and Gynaecology of The Chinese University of Hong Kong, as well as the Director of the Maternal Fetal Medicine of the same unit. His special interest is in prenatal screening, diagnosis and therapy of fetal abnormalities, ...
FofiFBgBiuAgArLueLBrBe3/./3ccT.nnATuuAKddK9ee09mm101iiicncieneh..hiAAbibifftitttseesrtrtuu77mmddooaaryrygsgs,,rrtoothhwweettththuuimimnnoovvrriisvsvowwo..eUeUrre8e87e7eMsMsttGaaGb-bLl-liLiUsshUhCeeCdcde.c.lTelTslhlhwseewemmreeiicrcieemewiwpmleeaprrneleatrenradatneniddndotooimnmttiho...